PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
The value of the US market is expected to fall following patent expiries for Eli Lilly’s Cymbalta in 2013, Otsuka Pharmaceutical/BMS’s Abilify in 2015, and AstraZeneca’s Seroquel XR in 2017. After a period of declining sales, GlobalData estimates that the MDD market in the US will follow a steady growth trend from 2018 to 2023.
Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting the US Major depressive disorder market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in the US.
Sales for Major Depressive Disorder (MDD) inthe US
GlobalData estimates the drug sales for MDD in2013 were approximately $7.5 billion in the UScovered in this forecast. By the end of the forecastperiod in 2023, sales will grow to approximately$7.6 billion with a Compound Annual Growth Rate(CAGR) of 0.12%.
The growth of the MDD market in the US is drivenby:
The launch of Lundbeck/Takeda’s Brintellix
The introduction of four adjunctive therapiesand three other antidepressant therapiesduring the forecast period
Increasing prevalent cases of MDD
Expanded access to medical care as a resultof healthcare reformsThe barriers to the growth of MDD market in theUS are:
Intense competition from available genericproducts
Key branded drug patent expiries leading tosales erosion